NCT05093517View on ClinicalTrials.gov

Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

November 10, 2021

Primary Completion Date

March 16, 2022

Study Completion Date

March 16, 2022

Conditions
Type 2 DiabetesGlucose Tolerance ImpairedInsulin Sensitivity
Interventions
DRUG

REMD-477

A biologic glucagon receptor agonist to which randomized subjects are assigned 2:1

DRUG

Placebo Subcutaneous injection

Placebo for REMD-477 to which subjects will be randomized 1:2.

Trial Locations (1)

78207

Texas Diabetes Institute, San Antonio

All Listed Sponsors
lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT05093517 - Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM | Biotech Hunter | Biotech Hunter